EcoDrugPlus

Nischarin

Ensembl ID : ENSVVUG00000026172
Gene Symbol: NISCH
3 Cross references
209 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSVVUG00000015894
Gene Symbol: NOS2
3 Cross references
163 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSVVUG00000026126
Gene Symbol: NOTCH1
3 Cross references
273 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSVVUG00000020620
Gene Symbol: NOTCH3
3 Cross references
200 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSVVUG00000009160
Gene Symbol: NFKB1
3 Cross references
200 Possible Orthologues:

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSVVUG00000002942
Gene Symbol: NFKB2
3 Cross references
124 Possible Orthologues:

Nuclear Factor, Erythroid 2 Like 2

Ensembl ID : ENSVVUG00000012641
Gene Symbol: NFE2L2
3 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSVVUG00000020260
Gene Symbol: NR1H2
3 Cross references
305 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSVVUG00000026170
Gene Symbol: NR1H3
3 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSVVUG00000018520
Gene Symbol: NR1H4
3 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSVVUG00000021086
Gene Symbol: NR3C1
3 Cross references
278 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSVVUG00000009451
Gene Symbol: NR3C2
3 Cross references
212 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).